Pulse Endovascular ReperFUSION for Acute Ischemic Stroke

Official title

PERFUSION AIS - Pulse Endovascular ReperFUSION for Acute Ischemic Stroke: An Early Feasibility Clinical Study

Overview

Prospective, multi-center, single-arm early feasibility study enrolling a minimum of 15 subjects at up to a minimum of 3 active investigational sites in the United States. The subjects must be diagnosed with acute ischemic stroke (AIS), must be post-mechanical thrombectomy, will have had intravenous thrombolytics, and have a visible MCA, ACA or PCA occlusive clot on initial angiographic imaging. Each subject will receive the Pulse NanoMED procedure after attempted neurovascular therapy to achieve better reperfusion.

Interventions

• Device Pulse NanoMED System
  The Pulse NanoMED System is comprised of iron nanoparticles and a small, portable, magnetic Workstation.

Primary outcome measures

• Primary Objective [Time frame: 24 hours, 7 days (or discharge, if earlier), 30 days, and 90 days post-procedure]

Secondary outcome measures (1)

• Secondary Objective [Time frame: 24 hours, 7 days (or discharge, if earlier), 30 days, and 90 days post-procedure]

Eligibility criteria

Inclusion criteria

• The participant provides written informed consent using an Informed Consent Form (ICF) that is reviewed and approved by the Institutional Review Board (IRB) or an acceptable patient surrogate.
• The participant is ≥ 18 years old and less than 85 years old.
• Patients with symptomatic large vessel occlusion (LVO) who undergo MT as part of their standard of care and have residual occlusion involving the anterior, middle or posterior cerebral arteries resulting in a eTICI score greater than 2b50 at the end of the procedure with three or less MT device passes.
• Estimated delay to onset of rescue Pulse NanoMED MicroBead administration <9 hours from symptom onset, defined as the point in time the patient was last known well (LKW).
• Post-MT and has had thrombolytic therapy <9 hours prior to the proposed start time of System therapy
• No significant pre-stroke functional disability (modified Rankin scale 0-1)
• Baseline NIHSS≥6
• ASPECTS >6 on non-contrast CT (NCCT) scan if symptoms lasting <8 hours
• CT-Perfusion (CTP) is optional, if performed, should demonstrate rCBF <30% lesion volume ≤70 mL.
• Imaging should be obtained within 75 minutes of the onset of mechanical thrombectomy.

Exclusion criteria

• NIHSS score on admission >25
• Use of carotid artery stents during the endovascular procedure requiring dual antiplatelet therapy
• Female who is pregnant or lactating or has a positive pregnancy test at the time of admission
• Current participation in another investigational drug or device treatment study
• Known allergy or sensitivity to iron
• Known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency
• Known coagulopathy, INR >1.7, or use of novel anticoagulants <12h from symptom onset
• Known Platelets <100,000
• Known Renal Failure as defined by a serum creatinine >3.0 mg/dl (or 265.2 μmol/l) or glomerular Filtration Rate \[GFR\] <30
• Subject who requires hemodialysis or peritoneal dialysis or who has a contraindication to angiogram for whatever reason
• Any hemorrhage on CT/MRI
• Clinical presentation suggests a subarachnoid hemorrhage, even if initial CT or MRI scan is normal.
• Suspicion of aortic dissection
• Subject currently uses or has a recent history of illicit drug(s) or abuses alcohol.
• History of life-threatening allergy (more than rash) to contrast medium
• SBP >185mmHg or DBP >110mmHg refractory to treatment
• Serious, advanced, terminal illness with anticipated life expectancy <6 months
• Pre-existing neurological or psychiatric disease that would confound evaluation
• Presumed vasculitis or septic embolization
• Known sensitivity or allergy to contrast materials that cannot be previously treated properly
• The subject takes Coumadin and its interruption could compromise their safety
• Known allergy or contraindication to double antiplatelet treatment
• Known hypersensitivity or contraindication to iron or polyethylene glycol-based agents
• Known contraindication to MRI (examples include, but are not known, implantable cardioverter-defibrillator, pacemaker, clip-on or spiral aneurysm, neurostimulator)
• The physical geometry of the subject that prevents the placement of the magnet
• The subject has signs or symptoms of systemic infection/sepsis (temperature of ≥38.0 Celsius and/or white blood cell count of ≥12,000 cells/uL). If the subject has a localized infection, such as cellulitis or osteomyelitis, or the infection is properly treated and controlled, according to the discretion of the researcher, the patient can enroll
• Known or suspected cardiovascular condition that causes a secondary or tertiary heart block, tachycardia-bradycardia syndrome, or symptomatic postural hypotension requiring medical intervention
• Known or suspected symptomatic hemochromatosis or hemosiderosis
• Known or suspected liver disease, such as hepatitis and/or cirrhosis
• The subject has received iron replacement therapy or contrast for iron-based MRI in the previous 30 days

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

N/A

Model

Single group

Masking

Open label

Primary purpose

Treatment

Study locations

United States · 1 center

• University of South Carolina - Prisma — Columbia

Identifiers

NCT: NCT06052969 · MED-CLN-001P · G220131/S001

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗